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Abstract Primary headaches such as migraine are among
the most prevalent neurological disorders, affecting up to
one-ﬁfth of the adult population. The scientiﬁc work in the
last decade has unraveled much of the pathophysiological
background of migraine, which is now considered to be a
neurovascular disorder. It has been discovered that the
trigemino-cerebrovascular system plays a key role in
migraine headache pathophysiology by releasing the potent
vasodilator calcitonin gene-related peptide (CGRP). This
neuropeptide is released in parallel with the pain and its
concentration correlates well with the intensity of the
headache. The development of drugs of the triptan class
has provided relief for the acute attacks but at the cost of,
mainly cardiovascular, side effects. Thus, the intention to
improve treatment led to the development of small CGRP
receptor antagonists such as olcegepant (BIBN4096BS)
and MK-0974 that alleviate the acute migraine attack
without acute side events. The purpose of this review is to
give a short overview of the pathological background of
migraine headache and to illustrate the mechanisms behind
the actions of triptans and the promising CGRP receptor
blockers.
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The trigemino-cerebrovascular system
Pain-sensitive structures such as the intracranial vessels
and the meninges, especially the dura mater, are supplied
with sensory nerve ﬁbers. In fact they are innervated by the
ophthalmic ramus of the ﬁrst branch of the trigeminal nerve
that arises from pseudounipolar neurons located in the
trigeminal ganglion. Those neurons project onto second
order sensory neurons in the trigmenial nucleus caudalis
(TNC) in the brain stem and its related extensions down to
the C2-level called the trigeminocervical complex [1].
From this region a signal is transmitted to the ventropos-
terior thalamus leading to activation in cortical areas,
including frontal cortex, insulae and cingulate cortex. This
results in the experience of pain (Fig. 1). In addition, a
migraine active region has been pointed out in the brain-
stem by using positron emission tomography (PET) [2–4].
Thus, an involvement of the trigemino-cerebrovascular
system in the transmission of nociceptive information to
the central nervous system is a viable position.
The trigemino-cerebrovascular reﬂex
There is a dense supply of CGRP-containing nerve ﬁbers
originating in the ﬁrst division of the trigeminal ganglion
that innervate intracranial vessels. Experimental studies
have shown that induction of vasoconstriction provoked
rapid normalization of the vascular tone due to––in part––
reﬂex activation of the trigeminal nerve. Vasoconstriction
triggers an antidromic release of sensory trigeminal neu-
ropeptides, mainly CGRP, being a strong intracranial
dilatator [5, 6]. After denervation there is no alteration in
the contractile response of the vessel but the time to attain
initial basal tone is markedly prolonged. This is of
importance as headache may be initiated by a spreading
wave of depression of cortical neurons resulting in con-
traction of some parts of the cerebral circulation. This
phenomenon has now been shown in man [7] and could
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reestablish the vascular tone. Thus, the trigemino-cere-
brovascular reﬂex is probably part of a counter-balancing
system, which is able to mediate dilatation of brain vessels
and sustain cerebral blood ﬂow [8]. This may assure the
maintenance of local brain blood ﬂow within normal limits
as the cerebral circulation requires high and constant ﬂow.
Activation of the neurons in the trigeminal ganglion leads
on the other hand to an activation of neurons in the tri-
geminocervical complex that project to the central nervous
system (CNS) and mediate the central aspects of pain
[1, 9].
Calcitonin gene-related peptide
CGRP is a neuropeptide consisting of 37 amino acids and
is predominantly expressed in the nervous system. It
originates from the calcitonin gene encoding calcitonin and
CGRP depending upon alternative splicing.
Histochemical studies of cerebral perivascular nerve
ﬁbers and human trigeminal ganglia revealed that almost
half of the cell bodies contain CGRP [10, 11]. Although
many other signal molecules are located in the trigeminal
ganglion, CGRP is the most abundant in man [12] and can
be seen as a marker for trigeminal activity. Furthermore it
is the only transmitter reliably released in acute migraine
attacks at present. There was a marked increase in CGRP
levels during migraine attacks, but no changes could be
observed for other neuropeptides such as vasoactive
intestinal peptide (a marker for parasympathetic activity),
neuropeptide Y (sympathetic activity) and substance P
(sensory activity) when their levels were analyzed in the
cranial venous outﬂow during migraine attacks [8, 13].
In migraine attacks elicited within clinical studies by
administration of nitroglycerin a good correlation has been
described between increased levels of CGRP and the
intensity of the headache [14, 15]. But it is noteworthy to
mention that nitroglycerin elicits head pain, but not always
genuine migraine attacks. There may be a need for the
subject to be in a ‘‘prone phase’’, where the trigemino-
cerebrovascular system might be hyper-reactive as it was
demonstrated in cluster headache [16].
Triptans
The increased cranial venous levels of CGRP observed in
conjunction with migraine attacks thus indicate activation
of the trigeminal system. Administration of sumatriptan––
belonging to the highly effective anti-migraine drugs called
triptans or 5-HT1B/1D agonists-results in alleviation of the
headache and normalization of the cranial venous CGRP
levels [8]. They are thought to act mainly as powerful
vasoconstrictors of cerebral vessels via 5-HT1B receptors,
which have been shown to be expressed in the medial
smooth muscle cell layer of the human middle meningeal
[17] and cerebral arteries [18].
In addition, triptans may bind to presynaptic 5-HT1B/1D
receptors on trigeminal afferents to inhibit nerve activity
and hence reduce CGRP release. 5-HT1B/1D receptors were
found on trigeminal sensory ﬁbers [19], trigeminal gan-
glion cells [20] and in the trigemino-cerebrovascular
system in man [21]. Furthermore, the 5-HT1B/1D receptors
were co-localized with CGRP in the human trigeminal
ganglion [20].
Autoradiographic studies using labeled zolmitriptan
conﬁrmed the presence of 5-HT1B/1D receptors in certain
brain stem nuclei that are involved in cranial nociceptive
processing [22] and are likely to be activated during
migraine.
Thus, it can be presumed that a potential relaxation of
intracranial blood vessels during migraine attacks can be
normalized by triptans, which activate the cerebrovascular
5-HT1B receptors and thereby cause vasoconstriction. By
stimulating 5-HT1B/1D receptors, triptans inhibit the release
of CGRP from the perivascular nerve terminals and the
trigeminal ganglion cells. Activation of 5-HT1B/1D recep-
tors at the level of the CNS (trigeminal nucleus caudalis)
may interrupt central aspects of the headache process.
Recently the relationship between pharmacokinetic and
pharmacodynamic aspects of triptans in migraine was
investigated. It has been observed that subcutaneous
Fig. 1 In migraine attacks, sensory nerves, which innervate the
cerebral blood vessels, are activated to antidromically release
calcitonin gene-related peptide. They originate from the ﬁrst branch
of the trigeminal nerve that arises from pseudounipolar neurons
located in the trigeminal ganglion (TG). Those neurons project onto
second order sensory neurons in the trigeminal nucleus caudalis
(TNC) from where a signal is transmitted to the cortex
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application. The difference in efﬁcacy is most likely due to
the rapid initial rise in plasma level after subcutaneous
administration [23]. Furthermore migraine attacks may
inﬂuence gastric stasis leading to delayed absorption of
drugs [24, 25]. Thus, to increase efﬁcacy of treatment,
attention should be paid to the development of migraine
drugs, which can be quickly absorbed.
Triptans cause sometimes cardiovascular adverse effects
as they also act as constrictors in coronary arteries. But
triptans are considered as more powerful vasoconstrictors
in human isolated cerebral arteries than in coronary arter-
ies. They are at least threefold more potent [26]. The reason
for the higher potency and efﬁciency of triptans in intra-
cranial arteries could be due to at least three differences.
First there is a higher number of 5-HT1B receptors in those
vessels compared to peripheral arteries [18, 27]. Secondly
there are few, if any, 5-HT2A receptors in intracranial
vessels whereas the 5-HT2A receptor population dominates
in coronary arteries [27]. Thirdly, there might be potential
differences in coupling of the 5-HT1B receptors between
cerebral and coronary arteries. In consideration of the fact
that triptans are weak constrictors in coronary arteries [28,
29] and have little impact on coronary blood ﬂow, the
clinical consequences in healthy subjects are minor.
However, small contractions may anyhow have propor-
tionally greater impact in diseased artery with luminal
narrowing. Triptans are hence contra-indicated in patients
with known cardiovascular disease.
Sensitization in migraine
Treatment with triptans achieves good results in patients
suffering from sensitization. Sensitization is deﬁned as an
increased afferent activity in response to an unchanged
stimulus [30] and both peripheral and central sensitization
may play a role in migraine attacks. Peripheral sensitiza-
tion of meningeal perivascular nociceptors arising from
trigeminal neurons can clinically explain phenomena like
intracranial hypersensitivity (worsening pain during phys-
ical activity) and the throbbing element in migraine pain.
This may be due to normally innocuous meningeal noci-
ceptors becoming hyper-responsive to rhythmic ﬂuctuation
in intracranial pressure that is produced by normal arterial
pulsations [31, 32].
Central sensitization of nociceptive second order neu-
rons in the trigeminocervical complex can be the reason for
extracranial tenderness and cutaneous allodynia. The latter
is an abnormal sensory state in which otherwise innocuous
stimuli are sensed as painful [31].
Two-thirds of patients develop allodynia during or even
after a migraine attack [33]. Based on clinical studies new
guidelines for triptan treatment in migraine has been
established. They include that allodynia-free patients can
receive good results from triptan treatment at any time
during the migraine attack. Furthermore, patients suffering
from allodynia can expect excellent results from triptans
before allodynia gets established. Therefore they should
take triptans as early as possible during the attack. After the
onset of allodynia, migraineurs can still beneﬁt from trip-
tans, but pain relief may be incomplete [34–36].
However,aslightlydifferentviewhasbeenexpressedina
recent study [37]. After subcutaneous administration of su-
matriptan, there was no difference in alleviation of migraine
pain irrespective if the drug was given early or late. There-
fore, it was suggested that the sensitization is of minor
importance and that the relatively poor effect of sumatriptan
lateinmigraineattacksisprimarilyduetogastricstasis[37].
CGRP receptors
Local vasodilatation and release of CGRP from the vas-
cular nerve ﬁber endings––caused by electrical ﬁeld
stimulation or capsaicin treatment [38, 39]––are attenuated
by administration of triptans, but also by application of
CGRP receptor blockers [40]. The proof that CGRP plays a
key role in migraine was provided by demonstrating that
the potent CGRP receptor antagonist olcegepant
(BIBN4096) could abort acute migraine attacks to a com-
parable degree as sumatriptan [41, 42]. In addition, CGRP
receptors are located at several sites, which play an
important role during migraine, including the cerebrovas-
culature [43–45], the trigeminocervical complex within the
brainstem [46] and the trigeminal ganglion [47].
Functional CGRP receptors consist of three components,
namely a seven-transmembrane domain G-protein coupled
receptor called calcitonin receptor-like receptor (CLR), a
receptor activity-modifying protein (RAMP) and a receptor
component protein (RCP). CLR shares 55% sequence
identity with the calcitonin receptor. Co-expression of CLR
with RAMP1 composes the CGRP receptor, while co-
expression of CLR with either RAMP2 or RAMP3 repre-
sents the adrenomedullin (AM) receptor or possibly a
combined receptor (CGRP and AM). Apart from contrib-
uting to the receptor speciﬁcity, RAMP1 is required for
glycosylation and transport of CLR to the plasma mem-
brane [48–50]. In addition, RAMP1 seems to be
functionally rate limiting for CGRP receptor activity in the
trigeminovascular system. It was proposed that elevated
RAMP1 expression could sensitize the trigeminal ganglion
of individuals to CGRP actions such as CGRP release and
neurogenic inﬂammation [47].
The third component of the CGRP receptor, the acces-
sory protein RCP, is required for proper biological function
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signaling pathways like the protein kinase A (PKA) path-
way [51]. Activation of CGRP receptors in cultured
trigeminal ganglion cells increased the cAMP levels, which
in turn led to elevated CGRP promoter activity and
increased CGRP mRNA levels. These results point to an
autoactivation of CGRP expression and indicate that ele-
vated release of CGRP in the trigeminal system may create
a self-sustaining feedback loop [47].
CGRP receptor antagonists olcegepant and MK-0974
The excellent correlation between CGRP release and
migraine headache has long pointed towards the potential
usefulness of a speciﬁc CGRP receptor antagonist in the
treatment of primary headaches [9, 52]. Thus, a series of
small molecule CGRP receptor blockers were developed.
Among those is olcegepant, which demonstrates extremely
high afﬁnity for human CGRP receptors, even higher
afﬁnity than the endogenous ligand [53]. Therefore it was
selected for further pharmacological investigations. Olce-
gepant was shown to be a pure antagonist for the human
CGRP receptor and to be selective against a broad panel of
enzymes and receptors such as calcitonin, amylin or
adrenomedullin receptors [54].
In isolated human temporal, middle meningeal and
cerebral arteries olcegepant effectively inhibits CGRP
induced dilatation [44, 55]. That may be due to the block of
the CGRP receptor as mRNA for CLR and RAMP1–3 has
been found in human middle meningeal arteries, cerebral
arteries as well as in microvessels [56] and CGRP receptor
components could be detected in the human cerebral vas-
culature [43]. In addition, olcegepant dose-dependently
inhibited vasodilatation induced by electrical stimulation of
the trigeminal ganglion in primates [54].
One major advantage of a CGRP receptor blocker is the
lack of vasoconstrictor ability. But blockade of the receptor
of a strong vasodilatation involves a theoretical risk of
causing both peripheral and cerebral vasoconstriction,
especially as high afﬁnity binding sites for CGRP have
been reported in the heart, liver, spleen, intestine, urogen-
ital system, skeletal muscles, and the skin [57–59]. But
olcegepant in doses up to 10 mg did not cause any clinical
relevant changes of vital signs like blood pressure and
pulse rate, in the ECG or in forearm blood ﬂow in healthy
volunteers [60]. Detailed studies of peripheral arteries such
as mesenteric and coronary arteries [44, 61] revealed that
those arteries show weaker responses to CGRP and lower
degree of antagonism by olcegepant. This is possibly
related to a lower number of CGRP receptors. In addition, a
study with seven healthy volunteers disclosed that olce-
gepant had no inﬂuence on cerebral blood ﬂow or on the
blood ﬂow velocity in the middle cerebral artery [62]. It
was concluded that CGRP receptor blockade has no effect
on the cerebral circulation in man.
However, it is still not clear where olcegepant acts as a
CGRP antagonist. It has been reported to inhibit (1) dila-
tation of dural arteries initiated by CGRP [63], (2) CGRP-
induced hypotension [40], and (3) increase in facial blood
ﬂow after trigeminal ganglion stimulation [54]. In contrast,
olcegepant did not signiﬁcantly inhibit changes in tone of
cerebral arterioles or of local cortical cerebral blood ﬂow
[40]. Those results indicate that olcegepant poorly pene-
trates the blood-brain barrier, but is very effective in
preventing vasodilatation of vessels without this feature
[64]. Thus, this CGRP receptor blocker was suggested to
exert its antagonistic effects mainly extracerebral, which
correlates with results from a study of healthy volunteers
[65]. In contrast, it was recently shown that CGRP-induced
relaxation of the rat middle cerebral artery can only be
inhibited by abluminally administered olcegepant as olce-
gepant was prevented from reaching the CGRP receptors
by the arterial endothelium [66]. These results suggest that
the anti-migraine effect of this CGRP receptor blocker is
on the abluminal side of the blood-brain barrier. This is
supported by the fact that olcegepant only has an antimi-
graine effect in high doses.
Anyhow, olcegepant was effective in a dose of 2.5 mg
in the treatment of acute migraine attacks [41]. The overall
treatment effect revealed a responder rate (a moderate to
severe headache going to mild or no headache) of 60% at
2 h after the start of the infusion compared with 27% in the
placebo group (Fig. 2). Thus, intravenous olcegepant was
found to be as efﬁcacious as oral sumatriptan in the relief
of acute attacks of migraine [42].
Signiﬁcant superiority over placebo was seen regarding
the pain-free rate at 2 h, the sustained pain relief at 24 h
and the improvement of nausea, photophobia and phono-
phobia (Fig. 3). The response was still rising at 4 h
pointing at a long duration of action. At 24 h the pain-free
rate was better than with triptans, suggesting a lower grade
of rebound.
The rate of recurrence was 19% as compared to a pla-
cebo rate of 46%. This is clearly lower than the recurrence
rate of triptans which usually is around 28% [42].
Safety and tolerability studies also showed that olcege-
pant is well tolerated. Adverse events were, in general,
minor and dose-dependent. Transient mild paresthesia was
the single most frequent adverse event [60].
One major disadvantage of olcegepant remains in its
structure. It is a hydrophilic molecule, has poor penetration
across the blood-brain barrier and is not suitable as an oral
drug. Considering the crucial advantages of an oral for-
mulation of a drug, a small-molecule, non-peptide CGRP
antagonist called MK-0974 was recently developed for the
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among others, tested in a noninvasive pharmacodynamic
model in rhesus monkeys, in which endogenous CGRP
release and a vasodilatatory response are achieved by
topical application of capsaicin to the forearm of the rhesus
monkey [68]. Infusion of different CGRP receptor antag-
onists inhibited the increase in local dermal blood ﬂow and
showed effectiveness with MK-0974 being the most potent
among them ([3.5-fold) [67]. In addition, MK-0974 dis-
played a low clearance (7.0 mL min
-1 kg
-1) and a good
i.v. half-life (2.8 h). The compound was ﬁnally chosen as a
clinical candidate, when it showed[10,000-fold selectivity
in assays including more than 160 receptors, transporters,
and enzymes [67].
Recently, MK-0974 has been tested in a randomized,
double-blind, placebo-and active-controlled, outpatient
study with a two-stage, dose-ranging design to test safety
and effectiveness [69]. Three hundred and thirty patients
suffering from migraine with and without aura were treated
with MK-0974 (in doses of 25–600 mg), rizatriptan
(10 mg) or placebo. As doses below 300 mg were insuf-
ﬁcient, they were discontinued. Thus, the overall treatment
effect was deﬁned as the average of the 300, 400, and
600 mg doses and showed signiﬁcance vs. placebo on the
primary endpoint (p = 0.015), which was deﬁned as pain
relief at 2 h after treatment (Fig. 2).
MK-0974 displayed also superior efﬁcacy vs. placebo for
secondary endpoints such as pain freedom at 2 h (overall
treatment effect p\0.001), sustained pain relief at 24 h
(overall treatment effect p\0.001) or sustained pain free-
dom at 24 h (overall treatment effect p\0.001) (Fig. 3). In
addition, MK-0974 provided relief of migraine-associated
symptoms such as photophobia, phonophobia and nausea.
Rizatriptan (10 mg) was used as an active control and
demonstrated effectiveness vs. placebo (p = 0.010) on the
primary endpoint deﬁned as pain relief at 2 h. By com-
parison, 300 and 600 mg doses of MK-0974 appeared to
work as well as rizatriptan or showed even numerical
superiority regarding the sustained pain freedom at 24 h
and the sustained pain relief at 24 h.
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versus placebo (left part)[ 69]. A dose of 2.5 mg of olcegepant also
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sumatriptan from another study [42] were added to demonstrate the
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erally well-tolerated. The reported side effects were mainly
nausea, dizziness and somnolence, but the incidence of
adverse experiences seemed to be comparable to the pla-
cebo group. In addition, there was no increase in adverse
events with increasing dose.
Thus, MK-0974 showed only mild side effects, but
signiﬁcant relief of migraine pain 2 h after treatment
compared to placebo and the relief was sustained through
24 h [69].
Conclusion
The novel CGRP receptor antagonists appear to be effec-
tive in the treatment of moderate and severe migraine
attacks. They do not only provide pain relief at 2 h, but also
show efﬁcacy regarding the secondary endpoints such as
pain freedom, improvement of associated symptoms and
functional disability [41, 69]. In addition, they show a
prolonged effect of action compared to the triptans. That
may suggest not only less rebound headache but perhaps
also a prophylactic possibility. Furthermore, only minor
adverse effects were reported and no cardiovascular side
effects could be seen so far. This is probably due to the
absence of vasoconstrictor properties and it also suggests
that vasoconstriction is not necessary to abort acute
migraine attacks. This lack of direct vasoconstrictor
activity may represent an important advantage over the
triptans. Further development of drugs against the CGRP
receptor will offer a new promising way of treatment.
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